Evidence on the longitudinal construct validity of major generic and utility measures of health-related quality of life in teens with depression

  • John F. Dickerson
  • David H. Feeny
  • Gregory N. Clarke
  • Alex L. MacMillan
  • Frances L. Lynch
Article

Abstract

Purpose

To examine the longitudinal construct validity in the assessment of changes in depressive symptoms of widely used utility and generic HRQL instruments in teens.

Methods

392 teens enrolled in the study and completed HRQL and diagnostic measures as part of the baseline interview. HRQL measures included EuroQol (EQ-5D-3L), Health Utilities Index Mark 2 (HUI2) and Mark 3 (HUI3), Quality of Well-Being Scale (QWB), Pediatric Quality of Life Inventory (PEDS-QL), RAND-36 (SF-6D), and Quality of Life in Depression Scale (QLDS). Youth completed follow-up interviews 12 weeks after baseline. Sixteen youth (4.1%) were lost to follow-up. We examined correlations between changes in HRQL instruments and the Children’s Depression Rating Scale-Revised (CDRS-R) and assessed clinically meaningful change in multi-attribute utility HRQL measures using mean change (MC) and standardized response mean (SRM) among youth showing at least moderate (20%) improvement in depression symptomology.

Results

Spearman’s correlation coefficients demonstrated moderate correlation between changes in CDRS-R and the HUI2 (r = 0.38), HUI3 (r = 0.42), EQ-5D-3L (r = 0.36), SF-6D (r = 0.39), and PEDS-QL (r = 0.39) and strong correlation between changes in CDRS-R and QWB (r = 0.52) and QLDS (r = − 0.71). Effect size results are also reported. Among multi-attribute utility measures, all showed clinically meaningful improvements in the sample of youth with depression improvement (HUI2, MC = 0.20, SRM = 0.97; HUI3, MC = 0.32, SRM = 1.17; EQ-5D-3L, MC = 0.08, SRM = 0.51; QWB, MC = 0.11, SRM = 0.86; and SF-6D, MC = 0.12, SRM = 1.02).

Conclusions

Findings support the longitudinal construct validity of included HRQL instruments for the assessment of change in depression outcomes in teens. Results of this study can help inform researchers about viable instruments to include in economic evaluations for this population.

Keywords

Longitudinal construct validity Health-related quality of life Teens Depression 

Notes

Acknowledgements

We thank Jill Pope for editorial support, and Allison Bonifay, Sue Leung, and Jeff Jensen for management and conduct of participant interviews.

Funding

The funding was provided by Agency for Healthcare Research and Quality (Grant No. R01-HS017720).

Compliance with ethical standards

Conflict of interest

It should be noted that David H. Feeny has a proprietary interest in Health Utilities Incorporated, Dundas, Ontario, Canada. HUI Inc. Distributes copyrighted Health Utilities Index (HUI) materials and provides methodological advice on the use of the HUI. No other authors have any conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Brent, D. A., & Weersing, V. R. (2008). Depressive disorders in childhood and adolescence. In M. Rutter, et al. (Eds.), Rutter’s child and adolescent psychiatry. Oxford: Blackwell Publishing Ltd. pp. 587–613.Google Scholar
  2. 2.
    Lynch, F. L., & Clarke, G. N. (2006). Estimating the economic burden of depression in children and adolescents. American Journal of Preventive Medicine, 31(6 Suppl 1), S143-51.PubMedGoogle Scholar
  3. 3.
    Smith, J. P., & Smith, G. C. (2010). Long-term economic costs of psychological problems during childhood. Social Science and Medicine (1982), 71(1), pp. 110–115.Google Scholar
  4. 4.
    Tunis, S. R., Stryer, D. B., & Clancy, C. M. (2003). Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. JAMA, 290(12), 1624–1632.CrossRefPubMedGoogle Scholar
  5. 5.
    Gold, M. R., et al. (1996). Cost-effectiveness in health and medicine. New York: Oxford Univeristy Press.Google Scholar
  6. 6.
    Drummond, M. (2001). Introducing economic and quality of life measurements into clinical studies. Annals of Medicine, 33(5), 344–349.CrossRefPubMedGoogle Scholar
  7. 7.
    Clarke, G. et al., (2016). Cognitive behavioral therapy in primary care for youth declining antidepressants: A randomized trial. Pediatrics. 137(5).Google Scholar
  8. 8.
    Emslie, G. J., Weinberg, W. A., & Mayes, T. L. (1998). Treatment of children with antidepressants: Focus on selective serotonin reuptake inhibitors. Depression and Anxiety, 8(Suppl1), 13–17.CrossRefPubMedGoogle Scholar
  9. 9.
    Hansen, R. et al. (2008). Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatric Services (Washington, D. C.), 59(10), 1121–1130.CrossRefGoogle Scholar
  10. 10.
    Jellinek, M. S., & Snyder, J. B. (1998). Depression and suicide in children and adolescents. Pediatrics in Review/American Academy of Pediatrics, 19(8), 255–264.Google Scholar
  11. 11.
    Brazier, J., et al. (2014). A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technology Assessment Health Technol Assess (Rockv) Health Technology Assessment (Winchester, England), 18(34), vii–viii, xiii–xxv, 1–188.Google Scholar
  12. 12.
    Gunther, O. H., et al. (2008). The responsiveness of EQ-5D utility scores in patients with depression: A comparison with instruments measuring quality of life, psychopathology and social functioning. Journal of Affective Disorders, 105(1–3), 81–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Byford, S. (2013). The validity and responsiveness of the EQ-5D measure of health-related quality of life in an adolescent population with persistent major depression. Journal of Mental Health (Abingdon, England), 22(2), 101–110.CrossRefGoogle Scholar
  14. 14.
    Lynch, F. L., et al. (2016). Measuring health-related quality of life in teens with and without depression. Medical Care, 54(12), 1089–1097.CrossRefPubMedGoogle Scholar
  15. 15.
    Brent, D., et al. (2008). Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA, 299(8), 901–913.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    March, J. S., et al. (2007). The treatment for adolescents with depression study (TADS): Long-term effectiveness and safety outcomes. Archives of General Psychiatry, 64(10), 1132–1143.CrossRefPubMedGoogle Scholar
  17. 17.
    Clarke, G., et al. (2005). A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. Journal of the American Academy of Child and Adolescent Psychiatry, 44(9), 888–898.CrossRefPubMedGoogle Scholar
  18. 18.
    Kaufman, J., et al. (1997). Schedule for Affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. Journal of the American Academy of Child and Adolescent Psychiatry, 36(7), 980–988.CrossRefPubMedGoogle Scholar
  19. 19.
    Poznanski, E. O., et al. (1984). Preliminary studies of the reliability and validity of the children’s depression rating scale. Journal of the American Academy of Child Psychiatry, 23(2), 191–197.CrossRefPubMedGoogle Scholar
  20. 20.
    Mayes, T. L., et al. (2010). Psychometric properties of the children’s depression rating scale-revised in adolescents. Journal of Child and Adolescent Psychopharmacology, 20(6), 513–516.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    De Civita, M., et al. (2005). Evaluating health-related quality-of-life studies in paediatric populations: Some conceptual, methodological and developmental considerations and recent applications. PharmacoEconomics, 23(7), 659–685.CrossRefPubMedGoogle Scholar
  22. 22.
    Feeny, D., et al. (2004). Comparing directly measured standard gamble scores to HUI2 and HUI3 utility scores: Group-and individual-level comparisons. Social Science and Medicine (1982), 58(4), 799–809.CrossRefGoogle Scholar
  23. 23.
    Feeny, D., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40(2), 113–128.CrossRefPubMedGoogle Scholar
  24. 24.
    Furlong, W. J., et al. (2001). The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Annals of Medicine, 33(5), 375–384.CrossRefPubMedGoogle Scholar
  25. 25.
    Torrance, G. W., et al. (1996). Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Medical Care, 34(7), 702–722.PubMedGoogle Scholar
  26. 26.
    Essink-Bot, M. L., Stouthard, M. E., & Bonsel, G. J. (1993). Generalizability of valuations on health states collected with the EuroQolc-questionnaire. Health Economics, 2(3), 237–246.CrossRefPubMedGoogle Scholar
  27. 27.
    Kaplan, R. M. (2003). The significance of quality of life in health care. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 12(Suppl 1), 3–16.CrossRefGoogle Scholar
  28. 28.
    Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21(2), 271–292.CrossRefPubMedGoogle Scholar
  29. 29.
    Hays, R. D., & Morales, L. S. (2001). The RAND-36 measure of health-related quality of life. Annals of Medicine, 33(5), 350–357.CrossRefPubMedGoogle Scholar
  30. 30.
    Varni, J. W., Seid, M., & Kurtin, P. S. (2001). PedsQL 4.0: Reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Medical Care, 39(8), 800–812.CrossRefPubMedGoogle Scholar
  31. 31.
    Donald Sherbourne, C., et al. (2001). Can utility-weighted health-related quality-of-life estimates capture health effects of quality improvement for depression? Medical Care, 39(11), 1246–1259.CrossRefPubMedGoogle Scholar
  32. 32.
    Hunt, S. M., & McKenna, S. P. (1992). The QLDS: a scale for the measurement of quality of life in depression. Health Policy (Amsterdam, Netherlands), 22(3), 307–319.CrossRefGoogle Scholar
  33. 33.
    Guyatt, G. H., et al. (1987). A measure of quality of life for clinical trials in chronic lung disease. Thorax, 42(10), 773–778.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Grootendorst, P., Feeny, D., & Furlong, W. (2000). Health Utilities Index Mark 3: Evidence of construct validity for stroke and arthritis in a population health survey. Medical Care, 38(3), 290–299.CrossRefPubMedGoogle Scholar
  35. 35.
    Horsman, J., et al. (2003). The Health Utilities Index (HUI): Concepts, measurement properties and applications. Health and Quality of Life Outcomes, 1, 54.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Walters, S. J., & Brazier, J. E. (2003). What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health and Quality of Life Outcomes, 1, 4.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Walters, S. J., & Brazier, J. E. (2005). Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 14(6), 1523–1532.CrossRefGoogle Scholar
  38. 38.
    Feeny, D., et al. (2005). A cohort study found the RAND-12 and Health Utilities Index Mark 3 demonstrated construct validity in high-risk primary care patients. Journal of Clinical Epidemiology, 58(2), 138–141.CrossRefPubMedGoogle Scholar
  39. 39.
    Marra, C. A., et al. (2005). A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Social Science and Medicine (1982), 60(7), 1571–1582.CrossRefGoogle Scholar
  40. 40.
    Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd edn.). New Jersey: Lawrence Erlbaum Associates.Google Scholar
  41. 41.
    Pyne, J. M., et al. (2003). Use of the quality of well-being self-administered version (QWB-SA) in assessing health-related quality of life in depressed patients. Journal of Affective Disorders, 76(1–3), 237–247.CrossRefPubMedGoogle Scholar
  42. 42.
    Sapin, C., et al. (2004). Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health and Quality of Life Outcomes, 2, 20.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Wiebe, S., et al. (2003). Comparative responsiveness of generic and specific quality-of-life instruments. Journal of Clinical Epidemiology, 56(1), 52–60.CrossRefPubMedGoogle Scholar
  44. 44.
    Turner, N., et al. (2013). A comparison of four different approaches to measuring health utility in depressed patients. Health and Quality of Life Outcomes, 11, 81.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    http://factfinder.census.gov. Accessed 1 Sep 2016.
  46. 46.
    Wille, N., et al. (2010). Development of the EQ-5D-Y: A child-friendly version of the EQ-5D. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 19(6), 875–886.CrossRefGoogle Scholar
  47. 47.
    Mihalopoulos, C., et al. (2014). Assessing outcomes for cost-utility analysis in depression: Comparison of five multi-attribute utility instruments with two depression-specific outcome measures. The British Journal of Psychiatry: The Journal of Mental Science, 205(5), 390–397.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • John F. Dickerson
    • 1
  • David H. Feeny
    • 2
    • 3
  • Gregory N. Clarke
    • 1
  • Alex L. MacMillan
    • 4
  • Frances L. Lynch
    • 1
  1. 1.Center for Health Research - Kaiser PermanentePortlandUSA
  2. 2.Department of EconomicsMcMaster UniversityHamiltonCanada
  3. 3.Health Utilities IncorporatedDundasCanada
  4. 4.ThinkShout, IncPortlandUSA

Personalised recommendations